Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model

International Journal of Oncology

Volumn 47, Issue 1, 2015, Pages 377-383

  Matsushima, Masashi ^a   Kikuchi, Eiji ^a   Matsumoto, Kazuhiro ^a   Hattori, Seiya ^a   Takeda, Toshikazu ^a   Kosaka, Takeo ^a   Miyajima, Akira ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bladder cancer; Intravesical therapy; MTOR; Novel antitumor agents; NVP BEZ235

Indexed keywords

DACTOLISIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; QUINOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER TRANSPLANTATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; METABOLISM; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MICE; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOLINES; TOR SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84931054033     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2995     Document Type: Article

References (39)

1. Hsieh JT, Dinney CP and Chung LW: The potential role of gene therapy in the treatment of bladder cancer. Urol Clin North Am 27: 103-113, ix, 2000.
2. Stein JP and Skinner DG: Radical cystectomy for invasive bladder cancer: Long-term results of a standard procedure. World J Urol 24: 296-304, 2006.
3. Bohle A and Brandau S: Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 170: 964-969, 2003.
4. Alexandroff AB, Jackson AM, O'Donnell MA and James K: BCG immunotherapy of bladder cancer: 20 years on. Lancet 353: 1689-1694, 1999
5. Bai X and Jiang Y: Key factors in mTOR regulation. Cell Mol Life Sci 67: 239-253, 2010.
6. Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562, 2009
7. Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083, 2010.
8. Seeliger H, Guba M, Kleespies A., Jauch KW and Bruns CJ: Role of mTOR in solid tumor systems: A therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 26: 611-621, 2007
9. Abe H and Kamai T Recent advances in the treatment of metastatic renal cell carcinoma. Int J Urol 20: 944-955, 2013.
10. Wada Y, Takahashi W, Kawano Y and Eto M: Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan. Int J Urol 19: 284-295, 2012.
11. Chiong E, Lee IL, Dadbin A, Sabichi A.L., Harris L., Urbauer D, McConkey DJ, Dickstein R.J., Cheng T and Grossman HB: Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 17: 2863-2873, 2011.
12. Fechner G, Classen K, Schmidt D., Hauser S and Müller SC: Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology 73: 665-668, discussion 668-669, 2009.
13. Makhlin I, Zhang J, Long C.J., Devarajan K., Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J and Boorjian SA: The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int 108: E84-E90, 2011.
14. Mansure JJ, Nassim R, Chevalier S., Rocha J, Scarlata E and Kassouf W: Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 8: 2339-2347, 2009
15. Serra V, Markman B, Scaltriti M., Eichhorn PJ, Valero V, Guzman M, Botero M.L., Llonch E., Atzori F, Di Cosimo S, et al.: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030, 2008.
16. Cho DC, Cohen MB, Panka D.J., Collins M., Ghebremichael M, Atkins MB, Signoretti S and Mier JW: The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 16: 3628-3638, 2010.
17. Maira SM, Stauffer F, Brueggen J., Furet P, Schnell C, Fritsch C., Brachmann S, Chêne P, De Pover A, Schoemaker K, et al.: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863, 2008.
18. Horiguchi Y, Kikuchi E, Ozu C., Nishiyama T, Oyama M, Horinaga M., Yoshioka K and Tachibana M: Establishment of orthotopic mouse superficial bladder tumor model for studies on intravesical treatments. Hum Cell 21: 57-63, 2008.
19. Horiguchi Y, Larchian WA, Kaplinsky R, Fair WR and Heston WD: Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther 7: 844-851, 2000.
20. Horinaga M, Harsch KM, Fukuyama R, Heston W and Larchian W: Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology 66: 461-466, 2005
21. Matsumoto K, Kikuchi E, Horinaga M., Takeda T, Miyajima A, Nakagawa K and Oya M: Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model. Hum Gene Ther 22: 1423-1432, 2011.
22. Fahmy M, Mansure JJ, Brimo F, Yafi F.A., Segal R., Althunayan A, Hicks J, Meeker A., Netto G and Kassouf W: Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer. Hum Pathol 44: 1766-1772, 2013.
23. Hansel DE, Platt E, Orloff M., Harwalker J, Sethu S, Hicks J.L., De Marzo A, Steinle RE, Hsi ED, Theodorescu D, et al.: Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol 176: 3062-3072, 2010.
24. Korkolopoulou P, Levidou G, Trigka E.A., Prekete N., Karlou M, Thymara I, Sakellariou S., Fragkou P, Isaiadis D, Pavlopoulos P, et al: A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU Int 110: E1237-E1248, 2012.
25. Park SJ, Lee TJ and Chang IH: Role of the mTOR pathway in the progression and recurrence of bladder cancer: An immunohistochemical tissue microarray study. Korean J Urol 52: 466-473, 2011.
26. Sun CH, Chang YH and Pan CC: Activation of the PI3K/Akt/ mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 58: 1054-1063, 2011.
27. Seager CM, Puzio-Kuter AM, Patel T., Jain S, Cordon-Cardo C, McKiernan J and Abate-Shen C: Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila) 2: 1008-1014, 2009
28. Vasconcelos-Nóbrega C, Pinto-Leite R, Arantes-Rodrigues R, Ferreira R, Brochado P, Cardoso ML, Palmeira C, Salvador A, Guedes-Teixeira CI, Colaço A, et al.: In vivo and in vitro effects of RAD001 on bladder cancer. Urol Oncol 31: 1212-1221, 2013.
29. Gerullis H, Eimer C, Ecke T.H., Georgas E., Freitas C, Kastenholz S, Arndt C., Heusch C and Otto T: A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Med Oncol 29: 2870-2876, 2012.
30. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F., Salmena L, Alimonti A, Egia A., Sasaki AT, Thomas G, Kozma SC, et al.: Inhibition of mTORCl leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074, 2008.
31. O'Reilly KE, Rojo F, She Q.B., Solit D., Mills GB, Smith D, Lane H, Hofmann F., Hicklin DJ, Ludwig DL, et al.: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508, 2006.
32. Gupta S, Hau AM, Beach J.R., Harwalker J., Mantuano E, Gonias SL, Egelhoff TT and Hansel DE: Mammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion. PLoS One 8: e81081, 2013.
33. Connor J, Bannerji R, Saito S., Heston W, Fair W and Gilboa E: Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 177: 1127-1134, 1993.
34. Fidler IJ: Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50: 6130-6138, 1990.
35. Ratliff TL Role of animal models in understanding intravesical therapy with bacille Calmette-Guérin. Clin Infect Dis 31 (Suppl 3): S106-S108, 2000.
36. Chin J, Kadhim S, Garcia B., Kim YS and Karlik S: Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants. J Urol 145: 1297-1301, 1991.
37. Weldon TE and Soloway MS: Susceptibility of urothelium to neoplastic cellular implantation. Urology 5: 824-827, 1975
38. Hsu CC, Chuang YC and Chancellor MB: Intravesical drug delivery for dysfunctional bladder. Int J Urol 20: 552-562, 2013.
39. Dalbagni G, Russo P, Sheinfeld J., Mazumdar M, Tong W, Rabbani F., Donat MS, Herr HW, Sogani P, dePalma D, et al.: Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20: 3193-3198, 2002.